3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
6
Pancreatic Neoplasms
5
Colonic Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Rectal Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hematologic Neoplasms
3
Esophageal Neoplasms
3
Biliary Tract Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Interventions
Docetaxel
4
Cetuximab
4
pembrolizumab
3
Trastuzumab
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Biopsy
3
trastuzumab deruxtecan
2
sargramostim
2
Taxes
2
SS1(dsFv)PE38
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
pertuzumab
1
oncogene protein E7, Human papillomavirus type 16
1
neratinib
1
mercaptoundecahydrododecaborate
1
larotrectinib
1
fluoromisonidazole
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pertuzumab
×
Gastrointestinal
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled